We are live on ! Find out more
EVLO

Evelo Biosciences, Inc. Common Stock
EVLO

Delisted

EVLO was delisted on the 11th of December, 2023.

Back to rankings

44 hedge funds and large institutions have $140M invested in Evelo Biosciences, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

88% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 8

50% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 6

7% more funds holding

Funds holding: 41 → 44 (+3)

22% less capital invested

Capital invested by funds: $180M → $140M (-$39.9M)

Holders
44
Holders Change
+3
Holders Change %
+7.32%
% of All Funds
0.71%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.05%
New
9
Increased
15
Reduced
8
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$454K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$254K
3
Citigroup
Citigroup
New York
+$185K
4
6CM
683 Capital Management
New York
+$179K
5
BFM
Boothbay Fund Management
New York
+$104K

Top Sellers

Rank Fund Capital Flow
1
CH
CVI Holdings
Delaware
-$440K
2
Millennium Management
Millennium Management
New York
-$180K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$107K
4
Bank of America
Bank of America
North Carolina
-$58.2K
5
E
Ergoteles
New York
-$57K
Name Holding Trade Value Shares
Change 		Change in
Stake
FP
1
Flagship Pioneering
Massachusetts
$81.2M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$26.4M +$454K +11,465 +1%
SOMRS
3
State of Michigan Retirement System
Michigan
$6.55M – – –
CS
4
Credit Suisse
Switzerland
$5.92M +$16.2K +410 +0.2%
Vanguard Group
5
Vanguard Group
Pennsylvania
$5.1M -$107K -2,702 -2%
HP
6
Harbourvest Partners
Massachusetts
$4.93M – – –
CH
7
CVI Holdings
Delaware
$2.37M -$440K -11,104 -13%
BlackRock
8
BlackRock
New York
$1.98M +$54.1K +1,366 +2%
AI
9
Alphabet Inc
California
$1.71M – – –
Geode Capital Management
10
Geode Capital Management
Massachusetts
$977K +$41.5K +1,048 +4%
MC
11
Mayo Clinic
Minnesota
$772K +$949K +23,962 New
State Street
12
State Street
Massachusetts
$245K +$75.7K +1,913 +34%
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
$235K +$254K +6,404 +712%
TOCUITCONY
14
Trustees of Columbia University in the City of New York
New York
$183K +$225K +5,693 New
BCM
15
Bridgeway Capital Management
Texas
$170K – – –
Citigroup
16
Citigroup
New York
$160K +$185K +4,674 +1,522%
Northern Trust
17
Northern Trust
Illinois
$153K -$594 -15 -0.3%
Millennium Management
18
Millennium Management
New York
$151K -$180K -4,541 -49%
6CM
19
683 Capital Management
New York
$145K +$179K +4,515 New
Morgan Stanley
20
Morgan Stanley
New York
$127K +$28.9K +729 +23%
Bessemer Group
21
Bessemer Group
New Jersey
$99K – – –
BFM
22
Boothbay Fund Management
New York
$84.8K +$104K +2,635 New
Man Group
23
Man Group
United Kingdom
$84.7K +$104K +2,632 New
Charles Schwab
24
Charles Schwab
California
$50.5K – – –
Goldman Sachs
25
Goldman Sachs
New York
$50.5K -$5.38K -136 -8%
1
2

EVLO Hedge Fund Activity: Q4 2022 in Review

44 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Evelo Biosciences, Inc. Common Stock (EVLO) for Q4 2022, worth a combined $140M — down 22% from $180M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new EVLO positions and 6 closed out — a net gain of 3 holders — while 15 added to existing stakes and 8 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $454K. The largest seller was CVI Holdings, cutting an estimated $440K.

  • 44 institutional investors held Evelo Biosciences, Inc. Common Stock (EVLO) as of Q4 2022, up from 41 in Q3 2022.
  • Funds reported $140M of Evelo Biosciences, Inc. Common Stock stock for Q4 2022, down 22% quarter-over-quarter.
  • 9 funds opened new Evelo Biosciences, Inc. Common Stock positions in Q4 2022 and 6 closed out, a net change of +3 holders.
  • The largest Evelo Biosciences, Inc. Common Stock buyer in Q4 2022 was Fidelity Investments, an estimated $454K added.
  • The largest Evelo Biosciences, Inc. Common Stock seller in Q4 2022 was CVI Holdings, an estimated $440K sold.

Based on aggregated 13F filings for Q4 2022.